Our products are built on the Click Neurobehavioral Intervention (CNI) platform and powered by Clickometrics®, our machine learning and data science engine.

Click Therapeutics develops and commercializes software as medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults.

OptiChroniX develops digital therapeutics dedicated to improving brain health. It develops an application that tracks disease progression and treatment effectiveness through the use of biometrics and digital biomarkers, integrated with care records and various medical and lifestyle repositories. The company was founded in 2020 and is based in Bottmingen, Switzerland.

OptiChroniX develops digital therapeutics dedicated to improving brain health. It develops an application that tracks disease progression and treatment effectiveness through the use of biometrics and digital biomarkers, integrated with care records and various medical and lifestyle repositories. The company was founded in 2020 and is based in Bottmingen, Switzerland.